Metabolic Benefits of Growth Hormone Therapy

Lanes, Roberto

doi:10.1007/978-3-319-28038-7_7

Cited by 2 publications

(3 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…First, in discussions with parents, it is important for clinicians to clearly distinguish between GH replacement for GH deficiency and pharmacologic GH treatment, such as for ISS, as the two clinical scenarios pose different risk-benefit considerations. Untreated GH deficiency has been associated with altered body composition (increased adiposity, decreased lean muscle mass), decreased bone mineralization, unfavorable plasma lipid and lipoprotein profiles and increased cardiovascular morbidity and mortality [22]. Thus, GH replacement for patients with GH deficiency provides health benefits beyond height.…”

Section: Discussionmentioning

confidence: 99%

Parental Concerns Influencing Decisions to Seek Medical Care for a Child's Short Stature

Grimberg

Cousounis

Cucchiara³

et al. 2015

Horm Res Paediatr

View full text Add to dashboard Cite

Aims: To examine parental concerns about child growth and factors that drive parents' decisions whether to intervene medically with their child's height. Methods: Parents of 9- to 14-year-old pediatric primary care patients of various heights, oversampled for those with short stature, participated in exploratory focus groups and nominal group technique sessions. Growth concerns expressed by the groups were incorporated into a survey, completed by 1,820 parents, and rated for their degree of impact on medical decision-making. Ordinal logistic regression modeled concern scores against parent traits. Explanatory focus groups clarified the survey results. Results: Research team consensus and factor analysis organized the 22 distinct concerns expressed by the parent groups into 7 categories. Categories rated as having the greatest influence on parental decision-making involved: treatment efficacy and side effects, child health and psychosocial function. Level of concern was highly associated with parental education and parenting style. Conclusion: Psychosocial issues are influential, but parental decision-making is most impacted by concerns about treatment and child health. By discussing the real risks and benefits of hormone treatment and addressing parents' perceptions of what is needed for physical and psychosocial health, clinicians can be highly effective educators to assure that treatment is used only as medically indicated.

show abstract

Section: Discussionmentioning

confidence: 99%

Parental Concerns Influencing Decisions to Seek Medical Care for a Child's Short Stature

Grimberg

Cousounis

Cucchiara³

et al. 2015

Horm Res Paediatr

View full text Add to dashboard Cite

show abstract

“…No study has addressed the effect of r-hGH on these parameters in acromegaly patients with GHD. Lp(a) is an independent atherogenic lipoprotein that can be thrombogenic and may be used as a plasma marker for individuals at risk for cardiovascular events (28) . AGHD has been shown to be associated with high Lp(a) that might add further risk to the already existed high cardiovascular risk (29) .…”

Section: Discussionmentioning

confidence: 99%

“…AGHD has been shown to be associated with high Lp(a) that might add further risk to the already existed high cardiovascular risk (29) . Studies have shown that treatment of childhood GHD leads to an increase in Lp(a) (28, 29) . However, Lp(a) rise with GH therapy in AGHD is not known.…”

Section: Discussionmentioning

confidence: 99%

Short-term efficacy of recombinant human GH therapy in cured acromegaly patients with GH deficiency: a single-center experience

Dutta¹,

Mahendran²,

Reddy³

et al. 2015

Endocrine Connections

View full text Add to dashboard Cite

The effectiveness and short-term safety of recombinant human GH (r-hGH) in acromegaly patients with GH deficiency (GHD) after treatment are not well established. The study includes ten subjects with acromegaly who had GHD treated with r-hGH for 6 months. Control groups consisted of ten age-, gender-, and BMI-matched healthy subjects and ten active acromegaly patients who were treatment naïve. Body composition, quality of life (QoL), muscle strength, lipid profile, and cardiovascular risk factors were assessed in all subjects at baseline, and the same parameters were reassessed after 6 months of therapy with r-hGH in acromegaly with GHD. Repeat magnetic resonance imaging of the sella was performed in treated subjects. Optical colonoscopy was done and biopsies were taken from multiple sites for proliferation indices (Ki67). The median duration of GHD was 17.8 months and dose of r-hGH administered was 5.7±1.5 μg/kg per day. There was improvement in bone mineral content (P=0.01), bone mineral density (P=0.04), muscle strength (P<0.001), total cholesterol (P=0.003), high-density cholesterol (P<0.001), and QoL – score (P=0.005), and reduction in low-density cholesterol (P=0.003) and triglyceride (P=0.004) after treatment. There was no change in lean body mass, total body fat, hsCRP, lipoprotein (a), and fibrinogen levels. There was a modest increase in plasminogen activator inhibitor 1 (P=0.002), but it was lower compared with healthy controls and treatment naïve acromegalics (P=0.007). Six month-r-hGH therapy improves body composition, atherogenic lipid profile, QoL, and muscle strength in GHD patients who had acromegaly. Long-term prospective studies are needed to evaluate the effect of r-hGH therapy in these patients.

show abstract

Metabolic Benefits of Growth Hormone Therapy

Cited by 2 publications

References 40 publications

Parental Concerns Influencing Decisions to Seek Medical Care for a Child's Short Stature

Parental Concerns Influencing Decisions to Seek Medical Care for a Child's Short Stature

Short-term efficacy of recombinant human GH therapy in cured acromegaly patients with GH deficiency: a single-center experience

Contact Info

Product

Resources

About